Reversal of Neuromuscular for Hip structure

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Cleveland Clinic, Cleveland, OH
Hip structure
Neostigmine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The investigators propose a randomized trial comparing sugammadex and neostigmine for the reversal of neuromuscular blocks induced by rocuronium or vecuronium in adults having general anesthesia with muscular block for re-do hip and knee orthopedic surgery.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 1 hour after surgery

1 hour after surgery
Complications related to urinary retention
Post-Void Bladder Volume

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Reversal of Neuromuscular
1 of 2
Neuromuscular Block
1 of 2
Active Control

286 Total Participants · 2 Treatment Groups

Primary Treatment: Reversal of Neuromuscular · No Placebo Group · Phase 3

Reversal of NeuromuscularActiveComparator Group · 2 Interventions: Neostigmine, Sugammadex · Intervention Types: Drug, Drug
Neuromuscular Block
Drug
ActiveComparator Group · 1 Intervention: Neostigmine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 hour after surgery
Closest Location: Cleveland Clinic · Cleveland, OH
Photo of Cleveland Clinic Administrative Campus Building 1 1Photo of Cleveland Clinic Administrative Campus Building 5 2Photo of Cleveland Clinic Crile Building 3
2004First Recorded Clinical Trial
0 TrialsResearching Hip structure
972 CompletedClinical Trials

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
929 Previous Clinical Trials
1,388,635 Total Patients Enrolled
Daniel I Sessler, MDStudy ChairThe Cleveland Clinic
31 Previous Clinical Trials
113,893 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a ASA physical status of 1, 2, or 3.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.